Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 335 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

335 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 335 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

335 programs

Clinical programs

Page 5 of 7

  1. Roflumilast

    Takeda

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  2. Romidepsin

    Takeda

    Lymphoma, T-Cell, Peripheral

    phase 2 small molecule terminated

    1 trial

  3. SHP611

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 small molecule active

    1 trial

  4. SHP648

    Takeda

    Hemophilia B

    phase 2 gene therapy terminated

    1 trial

  5. SHP655

    Takeda

    Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

    phase 2 small molecule completed

    1 trial

  6. SM101

    Takeda

    Immunoglobulin A Nephropathy

    phase 2 mab terminated

    1 trial

  7. SPD476-202

    Takeda

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  8. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial

  9. SPD489 20 mg

    Takeda

    Sleep Deprivation

    phase 2 small molecule completed

    1 trial

  10. SPD503 (Guanfacine HCl)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  11. SPD503 (extended-release Guanfacine hydrochloride)

    Takeda

    Generalized Anxiety Disorder (GAD)

    phase 2 small molecule completed

    1 trial

  12. SPD557

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule terminated

    1 trial

  13. SPD602

    Takeda

    Iron Overload Due to Repeated Red Blood Cell Transfusions

    phase 2 small molecule terminated

    1 trial

  14. SPD602

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule terminated

    2 trials

  15. SPD602 (FBS0701, SSP-004184)

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule completed

    1 trial

  16. SRM003

    Takeda

    Arteriovenous Graft

    phase 2 mab terminated

    1 trial

  17. SRM003

    Takeda

    Arteriovenous Fistula

    phase 2 mab completed

    1 trial

  18. SSP-002358 (0.1 mg) + PPI

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

  19. SSP-004184AQ

    Takeda

    Iron Overload Due to Repeated Red Blood Cell Transfusions

    phase 2 small molecule terminated

    1 trial

  20. SYR-619

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  21. Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

    Takeda

    Poliomyelitis

    phase 2 mab terminated

    1 trial

  22. Soticlestat

    Takeda

    Complex Regional Pain Syndrome

    phase 2 small molecule completed

    1 trial

  23. Soticlestat

    Takeda

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  24. Soticlestat

    Takeda

    15q Duplication Syndrome

    phase 2 small molecule completed

    1 trial

  25. Stem cells

    Takeda

    Rheumatoid Arthritis Aggravated

    phase 2 gene therapy completed

    1 trial

  26. Subcutaneous injection of TAK-850

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  27. TAK-007

    Takeda

    Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 mab active

    1 trial

  28. TAK-018

    Takeda

    Crohn Disease

    phase 2 small molecule terminated

    1 trial

  29. TAK-019

    Takeda

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  30. TAK-062

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  31. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  32. TAK-071

    Takeda

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  33. TAK-079

    Takeda

    Myasthenia Gravis

    phase 2 small molecule completed

    1 trial

  34. TAK-128

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule terminated

    2 trials

  35. TAK-186

    Takeda

    Squamous Cell Cancer of Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  36. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  37. TAK-226

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  38. TAK-272

    Takeda

    Type 2 Diabetes Mellitus and Microalbuminuria

    phase 2 small molecule completed

    1 trial

  39. TAK-279

    Takeda

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  40. TAK-279

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  41. TAK-279-CD-2001

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  42. TAK-279-UC-2001

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  43. TAK-279-VT-2001

    Takeda

    Non-segmental vitiligo

    phase 2 small molecule active

    1 trial

  44. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  45. TAK-280-1501

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  46. TAK-341

    Takeda

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  47. TAK-341-2001

    Takeda

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  48. TAK-360

    Takeda

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

335 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.